Abrahám G, Pogátsa-Murray G, Forster T, Csanády M, Sonkodi S
I. Belgyógyászati Klinika, Szent-Györgyi Albert Orvostudományi Egyetem, Szeged.
Orv Hetil. 1996 Jul 21;137(29):1583-6.
Numerous antihypertensive drugs exist with different modes of action, which have a really effective impact on hypertension. The life expectancy of hypertensive patients is known to depend on the degree of damage caused to their target organs by the hypertension itself. Cardiovascular hypertrophy and its complications are considered to be among the major elements of this process. This work evaluates the effectiveness of the long-term treatment of essential hypertensive subjects (n = 10) with a long-acting ACE-inhibitor, cilazapril, as concerns their blood pressure and cardiac hypertrophy. Cilazapril given orally in a daily dose of 2.5 mg effectively lowered both the systolic (delta 30 mm Hg) and the diastolic (delta 19 mm Hg) blood pressure. No changes were found in body weight or heart rate, and only one side-effects (skin rash) was reported. Cilazapril considerably decreased the left ventricular mass and hence the hypertrophic index of hypertensive patients with cardiac hypertrophy, suggesting that ACE inhibitors are effective not only in lowering blood pressure and decreasing hypertrophy, but also in lowering the cardiac morbidity and mortality.
有多种作用方式不同的抗高血压药物,它们对高血压有非常有效的影响。已知高血压患者的预期寿命取决于高血压本身对其靶器官造成的损害程度。心血管肥大及其并发症被认为是这一过程的主要因素之一。这项研究评估了长效血管紧张素转换酶抑制剂西拉普利对原发性高血压患者(n = 10)进行长期治疗在血压和心脏肥大方面的有效性。每日口服2.5毫克西拉普利可有效降低收缩压(下降30毫米汞柱)和舒张压(下降19毫米汞柱)。体重和心率未发现变化,仅报告了一例副作用(皮疹)。西拉普利显著降低了心脏肥大的高血压患者的左心室质量,从而降低了肥厚指数,这表明血管紧张素转换酶抑制剂不仅在降低血压和减轻肥厚方面有效,而且在降低心脏发病率和死亡率方面也有效。